Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Phytother Res ; 29(8): 1152-60, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25939344

ABSTRACT

Synergistic effect of supercritical CO2 extracts of Curcuma species with conventional chemotherapeutic drugs was investigated in human alveolar (SJRH30) and embryonal (RD) rhabdomyosarcoma cell lines. The Curcuma amada (mango ginger) (CA) extract showed the highest levels of cytotoxicity with inhibitory concentration IC50 values of 7.133 µg/ml and 7.501 µg/ml for SJRH30 and RD cell lines, respectively, as compared with Curcuma longa (turmeric) and Curcuma xanthorrhiza (Javanese turmeric) extracts. CA showed synergistic cytotoxic effects with vinblastine (VBL) and cyclophosphamide (CP) as indicated by the combination index values of <1 for VBL + CA, CP + CA, and VBL + CP + CA combinations in both embryonal and alveolar rhabdomyosarcomas. When lower doses of CA (0.1-0.2 µg/ml) were combined with cancer drugs like CP and VBL, caspase-3 activity increased significantly compared with individual agents and correlated with the percentage of apoptotic cells. CA in combination with VBL and CP induced a higher percentage of apoptosis than single agents in both cell lines. CA also modulated the expression of genes associated with intrinsic pathway of apoptosis (Bcl-2, Bax, Bak, and p53) and also inhibited the expression of genes associated with inflammation such as COX-2 and NF-κB. Xenograft studies with SJRH30 tumors in nude mice showed that CA treatment inhibited tumor growth rate with and without VBL and increased the survival rate significantly. These results suggest that CA can be evaluated further as an adjuvant with cancer drugs for the treatment of rhabdomyosarcoma patients. Copyright © 2015 John Wiley & Sons, Ltd.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Curcuma/chemistry , Plant Extracts/pharmacology , Rhabdomyosarcoma/pathology , Animals , Apoptosis/drug effects , Caspase 3/metabolism , Cell Line, Tumor/drug effects , Curcuma/classification , Cyclophosphamide/pharmacology , Drug Synergism , Humans , Inhibitory Concentration 50 , Male , Mice , Mice, Nude , NF-kappa B/metabolism , Vinblastine/pharmacology , Xenograft Model Antitumor Assays
2.
Int J Cancer ; 105(6): 784-9, 2003 Jul 20.
Article in English | MEDLINE | ID: mdl-12767063

ABSTRACT

Amooranin (AMR), a plant terpenoid, isolated from Amoora rohituka, was investigated for its ability to overcome multidrug resistance in human leukemia and colon carcinoma cell lines. AMR IC(50) values of multidrug-resistant leukemia (CEM/VLB) and colon carcinoma (SW620/Ad-300) cell lines were higher (1.9- and 6-fold) than parental sensitive cell lines (CEM and SW620). AMR induced G(2)+M phase-arrest during cell cycle traverse in leukemia and colon carcinoma cell lines and the percentage of cells in G(2)+M phase increased in a dose-dependent manner. Coincubation of tumor cells with both DOX and AMR reversed DOX resistance in 104-fold DOX-resistant CEM/VLB and 111-fold DOX-resistant SW620/Ad-300 cell lines with a dose modification factor of 50.9 and 99.6, respectively. Flow cytometric assay showed that AMR causes enhanced cellular DOX accumulation in a dose-dependent manner. AMR inhibits photolabeling of P-glycoprotein (P-gp) with [(3)H]-azidopine and the blocking effect enhanced with increasing concentrations of AMR. Our results show that AMR competitively inhibits P-gp-mediated DOX efflux, suggestive of a mechanism underlying the enhanced DOX accumulation and reversal of multidrug resistance by AMR.


Subject(s)
Antineoplastic Agents, Phytogenic/toxicity , Carcinoma/drug therapy , Colonic Neoplasms/drug therapy , Drug Resistance, Neoplasm , Leukemia/drug therapy , Triterpenes/toxicity , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Affinity Labels , Antineoplastic Agents, Phytogenic/chemistry , Azides , Carcinoma/metabolism , Cell Cycle/drug effects , Cell Survival/drug effects , Colonic Neoplasms/metabolism , Dihydropyridines , Dose-Response Relationship, Drug , Doxorubicin/metabolism , Doxorubicin/toxicity , Drug Resistance, Multiple , Humans , Leukemia/metabolism , Triterpenes/chemistry , Tumor Cells, Cultured
3.
Cancer Lett ; 184(1): 1-6, 2002 Oct 08.
Article in English | MEDLINE | ID: mdl-12104041

ABSTRACT

The inhibitory effect of curcumin, the yellow-colored pigment from turmeric, on telomerase activity was analyzed in human mammary epithelial (MCF-10A) and breast cancer (MCF-7) cells. Telomerase activity in MCF-7 cells is 6.9-fold higher than that of human mammary epithelial cells. In MCF-7 cells, telomerase activity decreased with increasing concentrations of curcumin, inhibiting about 93.4% activity at 100 microM concentration. The inhibition of telomerase activity in MCF-7 cells may be due to down-regulation of hTERT expression. Increasing concentrations of curcumin caused a steady decrease in the level of hTERT mRNA in MCF-7 cells whereas the level of hTER and c-myc mRNAs remained the same. Our results suggest that curcumin inhibits telomerase activity by down-regulating hTERT expression in breast cancer cells and this down-regulation is not through the c-myc pathway.


Subject(s)
Breast Neoplasms/enzymology , Curcumin/pharmacology , Enzyme Inhibitors/pharmacology , Telomerase/antagonists & inhibitors , Telomerase/metabolism , DNA-Binding Proteins , Dose-Response Relationship, Drug , Down-Regulation , Epithelial Cells/drug effects , Epithelial Cells/enzymology , Female , Humans , Proto-Oncogene Proteins c-myc/metabolism , RNA, Messenger/metabolism , RNA, Neoplasm/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Telomerase/genetics , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/enzymology
SELECTION OF CITATIONS
SEARCH DETAIL
...